BOSTON, Feb. 11, 2025 /PRNewswire/ -- Stellaromics, a pioneer in 3D spatial biology spun out of the laboratories of Karl Deisseroth (Stanford University) and Xiao Wang (MIT and Broad Institute), today ...
Appointments to bolster rapid scaling and execution of Pyxa™ spatial platform BOSTON, Feb. 10, 2026 /PRNewswire/ -- Stellaromics, a pioneer in high-resolution 3D spatial multi-omics, today announced ...
Stellaromics is a privately held company dedicated to pioneering breakthroughs in 3D spatial multi-omics. The company's mission is to empower researchers with cutting-edge tools that illuminate the ...
Stellaromics today launched Pyxa™, the first commercially available platform to deliver multiplexed 3D spatial transcriptomics in intact tissue up to 100 micrometers thick. The launch marks a ...
BOSTON, Nov. 2, 2023 /PRNewswire/ -- Stellaromics, a leading provider of in situ spatial multi-omics technology, today announced that the company has raised $25 million in a Series A financing round.
BOSTON, Feb. 10, 2026 /PRNewswire/ -- Stellaromics, a pioneer in high-resolution 3D spatial multi-omics, today announced the appointment of Stacie Weninger, PhD, and Steve McPhail to its Board of ...
Stellaromics, announced the completion of a Series B funding round in the amount of $80M. The round, led by Catalyst4 with participation from Stanford University Ventures, will support the development ...
BOSTON, Feb. 19, 2026 /PRNewswire/ -- Stellaromics today launched PyxaTM, the first commercially available platform to deliver multiplexed 3D spatial transcriptomics in intact tissue up to 100 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results